Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis

Oncogene volume 25, pages 6520–6527 (2006)Cite this article

Abstract

The tumor necrosis factor receptor (TNFR)-associated factor (TRAF) family of six adaptor proteins (TRAF1–6) links the TNFR superfamily to the nuclear factor kappa B (NF-κB) and activator protein-1 (AP-1) transcriptional activators. Unlike other TRAFs, TRAF6 is also involved in Toll-like/interleukin (IL)-1 receptor (TIR) signal transduction. Thus, inhibition of TRAF6 function could interrupt both CD40 (TNFR family) and IL-1 growth signals, pathways critical to myeloma proliferation. To block TRAF6-mediated IL-1 signaling, we constructed small interfering RNA (siRNA) against TRAF6. We found that siRNA targeting the TRAF6 C-terminal (siTRAF6C) receptor interaction domain specifically reduced only TRAF6 protein expression, without affecting TRAF2 or 5 levels, and substantially interfered with IL-1-induced NF-κB and c-Jun/AP-1 activation. Inhibition by siTRAF6C was concentration-dependent. SiTRAF6C also significantly reduced myeloma proliferation and enhanced apoptosis in a similar dose-dependent fashion in vitro. More importantly, marked siTRAF6C growth inhibition was detected in vivo when these cells were implanted into the bone marrow of irradiated normal mice. In contrast, introduction of siRNA derived from the TRAF6 Zn-finger domain or an irrelevant siRNA construct failed to alter cell growth or cell death. These studies suggest that TRAF6 may be a new molecular target to block cell signal transduction important for the survival and proliferation of multiple myeloma cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Aderem A, Ulevitch RJ . (2000). Nature 406: 782–787.

  • Armstrong AP, Tometsko ME, Glaccum M, Sutherland CL, Cosman D, Dougall WC . (2002). J Biol Chem 277: 44347–44356.

  • Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM et al. (2002). Blood 99: 3163–3168.

  • Berenson JR, Ma HM, Vescio R . (2001). Semin Oncol 28: 626–633.

  • Bharti AC, Takada Y, Shishodia S, Aggarwal BB . (2004). J Biol Chem 279: 6065–6076.

  • Callander NS, Roodman GD . (2001). Semin Hematol 38: 276–285.

  • Cao Z, Tanaka M, Regnier C, Rothe M, Yamit-hezi A, Woronicz JD et al. (1999). Cold Spring Harb Symp Quant Biol 64: 473–483.

  • Cao Z, Xiong J, Takeuchi M, Kurama T, Goeddel DV . (1996). Nature 383: 443–446.

  • Chatterjee M, Stuhmer T, Herrmann P, Bommert K, Dorken B, Bargou RC . (2004). Blood 104: 3712–3721.

  • Cheng G, Cleary AM, Ye ZS, Hong DI, Lederman S, Baltimore D . (1995). Science 267: 1494–1498.

  • Chung JY, Park YC, Ye H, Wu H . (2002). J Cell Sci 115: 679–688.

  • Corso A, Ferretti E, Lunghi M, Zappasodi P, Mangiacavalli S, De Amici M et al. (2005). Cancer 104: 118–125.

  • Eferl R, Wagner EF . (2003). Nat Rev Cancer 3: 859–868.

  • Feng X . (2005). IUBMB Life 57: 389–395.

  • Inoue J, Ishida T, Tsukamoto N, Kobayashi N, Naito A, Azuma S et al. (2000). Exp Cell Res 254: 14–24.

  • Kobayashi N, Kadono Y, Naito A, Matsumoto K, Yamamoto T, Tanaka S et al. (2001). EMBO J 20: 1271–1280.

  • Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A et al. (1999). Genes Dev 13: 1015–1024.

  • Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C et al. (2003). Clin Cancer Res 9: 1136–1144.

  • Naito A, Azuma S, Tanaka S, Miyazaki T, Takaki S, Takatsu K et al. (1999). Genes Cells 4: 353–362.

  • Nakanishi C, Toi M . (2005). Nat Rev Cancer 5: 297–309.

  • Pagnucco G, Cardinale G, Gervasi F . (2004). Ann NY Acad Sci 1028: 390–399.

  • Sanda T, Iida S, Ogura H, Asamitsu K, Murata T, Bacon KB et al. (2005). Clin Cancer Res 11: 1974–1982.

  • Sinha SK, Zachariah S, Quinones HI, Shindo M, Chaudhary PM . (2002). J Biol Chem 277: 44953–44961.

  • Tai YT, Li X, Tong X, Santos D, Otsuki T, Catley L et al. (2005). Cancer Res 65: 5898–5906.

  • Takeuchi M, Rothe M, Goeddel DV . (1996). J Biol Chem 271: 19935–19942.

  • Teoh G, Tai YT, Urashima M, Shirahama S, Matsuzaki M, Chauhan D et al. (2000). Blood 95: 1039–1046.

  • Vincent T, Mechti N . (2005). Leukemia Lymphoma 46: 803–811.

  • Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B et al. (2004). Cancer Res 64: 2016–2023.

  • Ye H, Arron JR, Lamothe B, Cirilli M, Kobayashi T, Shevde NK et al. (2002). Nature 418: 443–447.

Download references

Acknowledgements

We thank Christine Pan James for her assistance with the preparation of this manuscript. This work was supported by grants from the Myeloma Research Fund and the Annenberg, Kramer, Peninsula Community and Skirball Foundations.

Author information

Authors and Affiliations

  1. Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, USA

    H Chen, M Li, R A Campbell, H J Lee, C Wang, M S Gordon & J R Berenson

  2. Amgen Inc., Thousand Oaks, CA, USA

    K Burkhardt

  3. Department of Pathology and Children's Hospital, Harvard Medical School, Boston, MA, USA

    D Zhu

  4. Department of Pathology and Laboratory Medicine, Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA

    S G Li

  5. Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA

    Z Zeng

  6. Department of Microbiology, Immunology and Molecular Genetics, Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA

    B Bonavida

Authors
  1. H Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R A Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Burkhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S G Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H J Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Z Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M S Gordon
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. B Bonavida
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J R Berenson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J R Berenson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, H., Li, M., Campbell, R. et al. Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis. Oncogene 25, 6520–6527 (2006). https://doi.org/10.1038/sj.onc.1209653

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209653

Keywords

This article is cited by

Search

Advanced search

Quick links